Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars. By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.
Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being miglitol), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued). This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal adverse effects.
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01025765
- Locations
- 🇨🇳
National Taiwan University Hospital Department of Internal Medicine,, Taipei, Taiwan
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Jean-Patrice Baillargeon
- Target Recruit Count
- 52
- Registration Number
- NCT01019356
- Locations
- 🇨🇦
Université de Sherbrooke, Sherbrooke, Quebec, Canada
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 204
- Registration Number
- NCT01010100
Vildagliptin and Endothelium-dependent Vasodilatation
- Conditions
- Type 2 DiabetesEndothelial Dysfunction
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2010-11-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT01000688
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 124
- Registration Number
- NCT00970528
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00928889
- Locations
- 🇨🇳
Nanfang Hospital, the Affiliated South Hospital of the Southern Medical University, Guangzhou, China
🇨🇳Peiking University First Hospital, BeiJing, China
🇨🇳People's Liberation Army. The Military General Hospital of BeiJing, BeiJing, China
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15729
- Registration Number
- NCT00909051
Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)
- Conditions
- Diabetes MellitusImpaired Glucose ToleranceCoronary Artery Disease
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Aichi Gakuin University
- Target Recruit Count
- 150
- Registration Number
- NCT00858676
- Locations
- 🇯🇵
Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University, Nagoya, Japan
Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity
- Conditions
- Pediatric ObesityInsulin ResistanceImpaired Glucose ToleranceCardiovascular Disease
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Yale University
- Target Recruit Count
- 23
- Registration Number
- NCT00846521
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Acarbose Cardiovascular Evaluation Trial
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Coronary Heart DiseaseAcute Coronary SyndromeImpaired Glucose Tolerance
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 6526
- Registration Number
- NCT00829660
- Locations
- 🇨🇳
Shanghai Zhabei District Shibei Hospital, Shanghai, Shanghai, China
🇨🇳China Meitan General Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.